Completed × Tretinoin × Other hematologic neoplasm × Clear all TUD-APOLLO-064
Phase 3 Completed
135 enrolled
IMG-7289-CTP-101
Phase 1/2 Completed
45 enrolled 41 charts
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
Phase 3 Completed
105 enrolled 7 charts
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Phase 2 Completed
78 enrolled 8 charts
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Phase 3 Completed
106 enrolled 14 charts
APL0406
Phase 3 Completed
276 enrolled
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Phase 2 Completed
17 enrolled 8 charts
TCP-ATRA
Phase 1 Completed
17 enrolled
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
Phase 2 Completed
78 enrolled 10 charts
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation
Phase 3 Completed
144 enrolled
Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer
Phase 1 Completed
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2/3 Completed
920 enrolled
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
12 enrolled
All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 3 Completed
500 enrolled
DECIDER
Phase 2 Completed
204 enrolled
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
Phase 1 Completed
9 enrolled
Differentiation Induction in Acute Myelogenous Leukemia
Phase 1/2 Completed
24 enrolled
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
Phase 1/2 Completed
36 enrolled
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Phase 2 Completed
Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia
Phase 3 Completed
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 3 Completed
2,000 enrolled
CLAG ATRA AML
Phase 1 Completed
11 enrolled
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
Phase 3 Completed
420 enrolled
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Phase 2 Completed
35 enrolled
Phase II 5-Azacytidine Plus VPA Plus ATRA
Phase 2 Completed
34 enrolled 5 charts
A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 2 Completed
40 enrolled
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
Phase 3 Completed
168 enrolled
APL93: Timing of CxT and Role of Maintenance
Phase 3 Completed
576 enrolled